Neisseria meningitidis P64k protein

Modality

N. meningitidis P64k Protein

P64k is found in vaccine formulations as a Neisseria meningitidis high molecular weight protein for the prevention of meningococcal infections. P64k is an outer membrane lipoamide dehydrogenase that is used as an available immunological carrier as it is highly immunogenic in animals. And CimaVax EGF, a P64k conjugated cancer vaccine is approved by Cube.

Cimavax-EGF is a therapeutic cancer vaccine designed to produce neutralizing antibodies against EGF that inhibit the fusion of EGF and EGFR. CimaVax-EGF is the first class of therapeutic lung cancer vaccine that chemically compromises yeast-derived human EGF, and is linked with the P64K protein of N. meningitidis produced by Escherichia coli (E. coli), and an immunoadjuvant (aluminium hydroxide or Contained ISA51). The drug was developed by CIMAB, and Bioven has exclusive rights to CimaVax-EGF and Biotech Pharmaceuticals in the U.S. and China, respectively.

All Categories

Neisseria meningitidis P64k protein

Modality

N. meningitidis P64k Protein

Yaohai Bio-Pharma offers One-Stop CDMO Solution for N. meningitidis P64k

MICROBIAL CDMO

Quick Links

GET IN TOUCH

Get in touch